Condition
Uveitis
ClinicalTrials.gov condition label
Clinical trials
20 shownWide Field OCTA in Ocular DiseasesNCT07298174 · 2026-01-01
NOT_YET_RECRUITINGHigh Resolution Optical Coherence TomographyNCT05130385 · 2021-11-30
UNKNOWNBiomarkers of Common Eye DiseasesNCT04101604 · 2019-09-26
UNKNOWNFeasibility Study and Preliminary Application Study on Iris OCTANCT03631108 · 2018-10-01
UNKNOWNChronic Inflammatory Disease, Lifestyle and Treatment ResponseNCT03173144 · 2017-09-21
COMPLETEDLSFG-SKIN, Laser Speckle FlowgraphyNCT03660618 · 2017-05-23
TERMINATEDEvaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin HospitalNCT02998398 · 2015-10-01
COMPLETEDPhenomics in Autoimmune and Inflammatory DiseasesNCT02466217 · 2015-07-29
COMPLETEDAssessment of Retinal Nerve Fibre Layer by Optical Coherence Tomography in Uveitis Patients With PapilloedemaNCT01170481 · 2009-07-01
COMPLETEDIntravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot StudyNCT00855608 · 2009-03-01
UNKNOWNGenetics and Markers of Degenerative and Inflammatory Eye DiseasesNCT00647439 · 2008-03-27
COMPLETEDDaclizumab Injections to Treat Non-Infectious Sight-Threatening UveitisNCT00043667 · 2002-08-01
COMPLETEDDifferences in Genes and Proteins in Active and Controlled UveitisNCT00357266 · 2002-02-01
COMPLETEDHAT in Eye Complications of Behcet's DiseaseNCT00001865 · 1999-07-01
COMPLETEDTNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid ArthritisNCT00001862 · 1999-02-01
COMPLETEDThe Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid ArthritisNCT00001614 · 1997-07-01
COMPLETEDANTI-TAC THERAPY FOR UVEITISNCT00001526 · 1996-06-04
COMPLETEDSpontaneous Coronary Artery Dissection (SCAD) and AutoimmunityNCT03941184 · 1995-01-01
COMPLETEDTissue Studies of Human Eye DiseasesNCT00001310 · 1992-03-05
TERMINATEDThe Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid ArthritisNCT00012506
UNKNOWNCommon interventions
DaclizumabDRUG21: AID groupsOTHER12: Control groupsOTHER1adalimumabDRUG1Chicken type II collagenDRUG1Collection of blood samplesOTHER1Daclizumab (Zenapax)DRUG1EnbrelDRUG1High-resolution optical coherence tomography (High-Res-OCT)DEVICE1laser speckle flowgraphyDEVICE1OCTA (ZEISS)DIAGNOSTIC_TEST1Other (exploratory) exposure variablesOTHER1Primary exposure variableOTHER1Standard spectral domain OCT (SD-OCT)DEVICE1Switch from REMICADE® to INFLECTRA®OTHER1TNFR:FcDRUG1
Leading sponsors
National Eye Institute (NEI)9Assistance Publique - Hôpitaux de Paris2Insel Gruppe AG, University Hospital Bern1IRCCS San Raffaele1Mayo Clinic1Rafic Hariri University Hospital1Randy Kardon1Shanghai Eye Disease Prevention and Treatment Center1St. Franziskus Hospital1Sun Yat-sen University1University of Southern Denmark1
Trial status mix
COMPLETED12
UNKNOWN5
TERMINATED2
NOT_YET_RECRUITING1
Phase mix
PHASE13
PHASE23
NA1
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.